Sign in
CompletedNo phase

Post Market TRUST - U.S.A. Study

Key facts

Who runs it
Acessa Health, Inc.
Where
Augusta, Austin, Chicago, Falls Church, Jamaica Plain, Rochester, Santa Monica, Walnut Creek, and West Bloomfield, United StatesSee the 9 sites
Trial code
Status
Completed
People taking part
114 people enrolled
Started
12 Jun 2014
Ended
12 Sept 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Global Fibroid Ablation (GFA)
  • Abdominal or Laparoscopic Myomectomy
  • Uterine Artery Embolization (UAE)
Record updated
30 September 2025

Who can take part

Age
18 years and older
Sex
Women only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Are ≥ 18 years old and menstruating
  • Have symptomatic uterine fibroids
  • Have a uterine size ≤ 16 gestational weeks as determined by pelvic exam
  • Have all fibroids that are less than 10 cm in any diameter
  • Desire uterine conservation
  • Have had a normal Pap smear within the past 36 months defined as "no untreated cervical malignancy or dysplasia."
  • Are willing and able to comply with all study tests, procedures, and assessment tools
  • Are capable of providing informed consent

Who cannot take part

  • Have contraindications for laparoscopic surgery and/or general anesthesia
  • Patients requiring major elective concomitant procedures (e.g., hernia repair)
  • Have taken any depot gonadotropin releasing hormone (GnRh) agonist within three months prior to the screening procedures
  • Have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed at least 10 days prior to treatment
  • Have had pelvic radiation
  • Have active or history of pelvic inflammatory disease
  • Have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the past five years
  • Are expected to be high risk for, or are known to have, significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus)
  • Are pregnant or lactating
  • Have chronic pelvic pain known to not be due to uterine fibroids
  • Have known or suspected endometriosis Stage 3 or 4, adenomyosis
  • Have a non-uterine pelvic mass over 3 cm
  • Have a cervical myoma
  • Have one or more completely intracavitary submucous fibroids (Type 0) or only Type 0/1 submucous fibroids that are better treated via hysteroscopic methods
  • In the medical judgment of the investigator should not participate in the study
  • Are not willing to be randomized to treatment

Where in United States

  • Augusta UniversityAugusta, United States
  • Texas Fertility CenterAustin, United States
  • University of Chicago, Medicine and Biological SciencesChicago, United States
  • INOVAFalls Church, United States
  • Brigham and Women's HospitalJamaica Plain, United States
  • University of Rochester Medical CenterRochester, United States
  • University of California, Los AngelesSanta Monica, United States
  • Aspen Surgery Center/John Muir HospitalWalnut Creek, United States
  • Henry Ford HospitalWest Bloomfield, United States

About the trial

What the trial wants to find out

This Post Market study is being conducted to compare the direct and indirect cost of three approaches (GFA, myomectomy, and uterine artery embolization) for the treatment of symptomatic uterine fibroids. In addition, data from this study is being used to satisfy the requirements of the United States Food and Drug Administration's 522 (post market surveillance) order.

The 2 groups in the trial

  • Ablation vs EmbolizationExisting treatment, for comparison

    Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)

    Treatment: Global Fibroid Ablation (GFA) and Uterine Artery Embolization (UAE)

  • Ablation vs MyomectomyExisting treatment, for comparison

    Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)

    Treatment: Global Fibroid Ablation (GFA) and Abdominal or Laparoscopic Myomectomy

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study
Record updated
30 September 2025